Skip to main
ABSI

Absci Corp (ABSI) Stock Forecast & Price Target

Absci Corp (ABSI) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Absci is a promising biotech company with a unique and efficient AI-powered platform for designing protein therapeutics. Their leading candidate ABS-201 has projected peak sales of $2.2B and their partnership with major pharmaceutical companies validates their technology in multiple therapeutic areas. Additionally, their other drug HMI-115 has potential for both endometriosis and hair growth, and their financial model is being updated to reflect the potential revenue from treating hair loss. While there are risks, the overall outlook is positive with a Buy rating and increased price target.

Bears say

Absci is heavily reliant on third-party suppliers for product manufacturing, and there is a risk of delays or disruptions in supply, which could negatively impact the company's clinical trials and potential commercialization. While the company's lead asset, ABS-201, has shown promising results in preclinical studies for conditions like androgenetic alopecia and endometriosis, there are regulatory and financial risks associated with bringing the drug to market. Additionally, there is no guarantee that ABS-201 will establish a more favorable safety and efficacy profile compared to existing treatments in these indications.

Absci Corp (ABSI) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Absci Corp (ABSI) Forecast

Analysts have given Absci Corp (ABSI) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Absci Corp (ABSI) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Absci Corp (ABSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.